Cutting Edge: Inhibition of the Interaction of NK Inhibitory Receptors with MHC Class I Augments Antiviral and Antitumor Immunity.
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
received:
21
04
2020
accepted:
22
05
2020
pubmed:
1
7
2020
medline:
16
3
2021
entrez:
1
7
2020
Statut:
ppublish
Résumé
NK cells recognize MHC class I (MHC-I) Ags via stochastically expressed MHC-I-specific inhibitory receptors that prevent NK cell activation via cytoplasmic ITIM. We have identified a pan anti-MHC-I mAb that blocks NK cell inhibitory receptor binding at a site distinct from the TCR binding site. Treatment of unmanipulated mice with this mAb disrupted immune homeostasis, markedly activated NK and memory phenotype T cells, enhanced immune responses against transplanted tumors, and augmented responses to acute and chronic viral infection. mAbs of this type represent novel checkpoint inhibitors in tumor immunity, potent tools for the eradication of chronic infection, and may function as adjuvants for the augmentation of the immune response to weak vaccines.
Identifiants
pubmed: 32601097
pii: jimmunol.2000412
doi: 10.4049/jimmunol.2000412
pmc: PMC7369225
mid: NIHMS1599417
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Receptors, Natural Killer Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-572Subventions
Organisme : Intramural NIH HHS
ID : Z01 AI000224
Pays : United States
Références
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Trends Immunol. 2011 May;32(5):219-24
pubmed: 21411368
J Immunol. 1981 Sep;127(3):923-30
pubmed: 6167633
Mol Immunol. 2017 Aug;88:138-147
pubmed: 28644973
J Immunol. 1980 Dec;125(6):2473-7
pubmed: 7191868
Nature. 1986 Feb 20-26;319(6055):675-8
pubmed: 3951539
PLoS Pathog. 2018 Apr 19;14(4):e1006985
pubmed: 29672594
Clin Cancer Res. 2016 Nov 1;22(21):5211-5222
pubmed: 27307594
Annu Rev Immunol. 2002;20:853-85
pubmed: 11861620
Curr Top Microbiol Immunol. 2016;395:37-61
pubmed: 26305047
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):599-608
pubmed: 30587590
Immunogenetics. 2017 Aug;69(8-9):547-556
pubmed: 28699110
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15849-54
pubmed: 19805228
Trends Immunol. 2013 Apr;34(4):182-91
pubmed: 23414611
J Exp Med. 2001 Jan 15;193(2):147-58
pubmed: 11148219
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):522-531
pubmed: 31871169
Immunity. 2012 Jun 29;36(6):1047-59
pubmed: 22749354
J Exp Med. 2019 Jan 7;216(1):99-116
pubmed: 30559128
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021889
J Biol Chem. 2002 Jan 11;277(2):1433-42
pubmed: 11696552
Nature. 1992 Jul 2;358(6381):66-70
pubmed: 1614533
Immunity. 1999 Nov;11(5):591-601
pubmed: 10591184
Immunol Rev. 1997 Feb;155:5-9
pubmed: 9059878
Front Immunol. 2014 Mar 26;5:123
pubmed: 24723923
J Immunol. 2002 Mar 15;168(6):2585-9
pubmed: 11884419
Clin Cancer Res. 2014 Mar 1;20(5):1095-103
pubmed: 24590885
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
Annu Rev Biophys Biomol Struct. 2003;32:93-114
pubmed: 12471063